OncoSec Medical Inc. (OTCQB: ONCS),
a company developing DNA-based intratumoral cancer immunotherapies, will
present new data from clinical studies evaluating the Company’s
ImmunoPulse immunotherapy in patients with melanoma at Melanoma Bridge
2014. The event is scheduled to take place at the Royal Continental
Hotel in Naples, Italy from December 3-6, 2014.
OncoSec’s Chief Medical Officer, Mai H. Le, M.D., commented: “We are
looking forward to a great Melanoma Bridge meeting in December and are
particularly excited to present both our long-term follow-up data from
the Phase 1 trial and the final overall response data from the recently
completed Phase 2 study in metastatic melanoma.”
Robert H. Pierce, M.D., Chief Scientific Officer, added “The positive
findings from these monotherapy trials really set the stage for our
next, critical study in melanoma – testing the combination of IL-12 gene
transfer with an anti-PD1/PDL1 therapeutic.”
Data from the two clinical studies evaluating the safety and efficacy of
intratumoral electroporation of plasmid interleukin-12 in patients with
metastatic melanoma will be featured in separate abstract discussion
sessions.
Abstract: Long-term overall survival from a phase I trial using
intratumoral plasmid interleukin-12 with electroporation in patients
with melanoma (Adil Daud, Kathryn Toshimi Takamura, Tu Diep, Richard
Heller, Robert H. Pierce).
When: Thursday, December 4th, 2014. 6:05 PM CET
Abstract: Intratumoral electroporation of plasmid interleukin-12:
efficacy and biomarker analyses from a phase 2 study in melanoma
(OMS-I100) (Adil Daud, Alain Algazi, Michelle Ashworth, Michael Buljan,
Kathryn Toshimi Takamura, Tu Diep, Robert H. Pierce, Shailender Bhatia).
When: Friday, December 5th, 2014. 5:40 PM CET
About Melanoma Bridge 2014
Melanoma Bridge 2014 aims to achieve a broad-based participation by
various groups and societies sharing a clinical or basic interest in the
immunology and the biology of the cancer microenvironment. The
Scientific Board of Melanoma Bridge includes well-known experts from
around the world covering a variety of different areas and specialties.
The event is being jointly organized by Istituto Nazionale Tumori
Fondazione "G. Pascale", Fondazione Melanoma Onlus and Sidra Medical and
Research Center, together with the Society for Immunotherapy of Cancer
(SITC). For more information, please visit: http://www.melanomabridge.org
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its
ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical's core
technology is designed to enhance the local delivery and uptake of DNA
IL-12 and other DNA-based immune-targeting agents. Clinical studies of
ImmunoPulse have demonstrated an acceptable safety profile and
preliminary evidence of anti-tumor activity in the treatment of various
skin cancers, as well as the potential to initiate a systemic immune
response without the systemic toxicities associated with other
treatments. OncoSec's lead program evaluating ImmunoPulse for the
treatment of metastatic melanoma is currently in Phase 2 development,
and is being conducted in collaboration with several prominent academic
medical centers. As the company continues to evaluate ImmunoPulse in its
current indications, it is also focused on identifying and developing
new immune-targeting agents, investigating additional tumor indications,
and evaluating combination-based immunotherapy approaches. For more
information, please visit www.oncosec.com.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such “forward-looking statements.” Forward-looking statements
are based on management’s current preliminary expectations and are
subject to risks and uncertainties, which may cause our results to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or commercialize new
products, uncertainties inherent in pre-clinical studies and clinical
trials, unexpected new data, safety and technical issues, competition,
and market conditions. These and additional risks and uncertainties are
more fully described in OncoSec Medical’s filings with the Securities
and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are
made. OncoSec Medical disclaims any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
Copyright Business Wire 2014